Park, Juhyung http://orcid.org/0009-0008-6916-2784
Wu, Jibo
Szkop, Krzysztof J.
Jeong, Jinho http://orcid.org/0000-0002-1224-7196
Jovanovic, Predrag http://orcid.org/0000-0002-0090-0047
Husmann, Dylan http://orcid.org/0000-0003-1995-7892
Flores, Natasha M.
Francis, Joel W.
Chen, Ying-Jiun C. http://orcid.org/0000-0002-6290-0771
Benitez, Ana Morales http://orcid.org/0000-0002-1021-5262
Zahn, Emily
Song, Shumei http://orcid.org/0000-0002-8128-6287
Ajani, Jaffer A. http://orcid.org/0000-0001-9946-0629
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Singh, Kamini
Larsson, Ola http://orcid.org/0000-0003-1412-1308
Garcia, Benjamin A. http://orcid.org/0000-0003-3596-4750
Topisirovic, Ivan http://orcid.org/0000-0002-5510-9762
Gozani, Or http://orcid.org/0000-0002-1365-4463
Mazur, Pawel K. http://orcid.org/0000-0002-5820-8344
Article History
Received: 26 July 2023
Accepted: 14 June 2024
First Online: 24 July 2024
Competing interests
: O.G. is a co-scientific founder and stockholder of EpiCypher, K36 Therapeutics and Alternative Bio. P.K.M. is a consultant and stockholder of Ikena Oncology and Alternative bio. The other authors declare no competing interests.